Clinical trials: Osler-Rendu Disease
Telangiectasia, Hereditary Hemorrhagic, Osler-Rendu Disease
ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome
Scientific Objectives Primary objective : Demonstrate that oral intake of tranexamic acid significantly reduces the risk of epistaxis occurrence, estimated by the average monthly duration of episodes of epistaxis.
- Trial name
- NCT00355108
- Testing
- tranexamic acid
- Where
- France
- Volunteers
- 170 people
- Sponsor
- Hospices Civils de Lyon
Hereditary Hemorrhagic Telangiectasia, Nosebleeds
Sirolimus for Nosebleeds in HHT
This pilot study is to determine the safety and efficacy of oral sirolimus (blood trough level 6-10ng/ml) in patients with HHT that are experiencing moderate or severe epistaxis.
- Conditions
- Hereditary Hemorrhagic Telangiectasia, Nosebleeds, Epistaxis
- Trial name
- NCT05269849
- Testing
- Sirolimus
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Unity Health Toronto
Hereditary Hemorrhagic Telangiectasia
Ultra-low-dose Chest CT for HHT
This study aims to develop a novel ultra-low dose chest CT technology for use in Hereditary Hemorrhagic Teleangiectasia (HHT) patients and to determine the lowest possible radiation dose that is achievable without sacrificing the…
- Trial name
- NCT04874558
- Testing
- Ultra-low dose chest CT
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Mayo Clinic
Hereditary Hemorrhagic Telangiectasia, Idiopathic Vascular Ectasia
Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study
This study will evaluate patients > 18 years of age with transfusion-dependent gastrointestinal bleeding due to documented gastrointestinal vascular ectasia with or without concurrent hereditary hemorrhagic telangiectasia (HHT).
- Trial name
- NCT02287558
- Testing
- Pomalidomide
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- The Cleveland Clinic
Hereditary Hemorrhagic Telangiectasia (HHT)
Frequency of Common Medical Conditions in People With and Without HHT
Hereditary Hemorrhagic Telangiectasia (HHT) affects 1 in 5,000 people. The purpose of this study is to provide data regarding the frequency of common health conditions and the tolerability of therapies in HHT by using a…
- Trial name
- NCT02464644
- Testing
- Questionnaire
- Where
- United Kingdom
- Volunteers
- 2,174 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Hereditary Hemorrhagic Telangiectasia (HHT)
Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Terence M. Davidson, MD is conducting a research study to find out more about the topical application of Avastin (proper chemical name is bevacizumab) in the treatment of epistaxis (nose bleeding) in patients with Hereditary…
- Trial name
- NCT01397695
- Testing
- Bevacizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Diego
Pulmonary Arteriovenous Malformations, Hereditary Hemorrhagic Telangiectasia
Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs With and Without Airflow Obstruction
Pulmonary arteriovenous malformations (PAVMs) are a rare vascular condition affecting the lungs. PAVMs lead to low blood oxygen levels, yet are very well tolerated by patients.
- Conditions
- Pulmonary Arteriovenous Malformations, Hereditary Hemorrhagic Telangiectasia, Asthma, COPD
- Trial name
- ExercisePAVM2 (NCT02458703)
- Testing
- Cardiopulmonary exercise test
- Volunteers
- 60 people
- Sponsor
- Imperial College London
Epistaxis, Hereditary Hemorrhagic Telangiectasia
Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia
The purpose of this study is to test a novel and tolerable office-based treatment method, sclerotherapy with sodium tetradecyl sulfate, for recurrent epistaxis (nosebleeds) related to Hereditary Hemorrhagic Telangiectasia (HHT)…
- Trial name
- NCT01408732
- Testing
- Sclerotherapy, Standard Treatment
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Minnesota
Hereditary Hemorrhagic Telangiectasia, HHT
Genotype-phenotype Association in Hereditary Hemorrhagic Telangiectasia
The present project aims to study the inflammatory and endothelial responses involved in the differences in clinical events related to both genotypes (ENG vs. ACVRL1) in HHT.
- Conditions
- Hereditary Hemorrhagic Telangiectasia, HHT, Rendu Osler Weber Disease
- Trial name
- Generate-HHT (NCT05550376)
- Testing
- Registry
- Where
- Spain
- Volunteers
- 85 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Pulmonary Arteriovenous Malformation
Microvascular Plug (MVP) for the Treatment of Pulmonary ArterioVenous Malformations (PAVMs)
The purpose of this study is to compare the use of the Micro Vascular Plug (MVP) system and other embolic devices in treatment of PAVMs.
- Trial name
- NCT04396041
- Testing
- Microvascular Plug (MVP), Amplatzer Vascular Plug (AVP), Detachable coils
- Where
- United States
- Volunteers
- 223 people
- Sponsor
- Johns Hopkins University
Haemorrhagic Hereditary Telangiectasia
Institutional Registry of Haemorrhagic Hereditary Telangiectasia
The purpose of this study is to create an institutional and population-based registry of Haemorrhagic Hereditary Telangiectasia with a prospective survey based on epidemiological data, risk factors, diagnosis, prognosis…
- Trial name
- NCT01761981
- Where
- Argentina
- Volunteers
- 590 people
- Sponsor
- Hospital Italiano de Buenos Aires
Hereditary Hemorrhagic Telangiectasia (HHT)
Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
This is a research study to find out more about the use of Avastin (proper chemical name is bevacizumab) in the treatment of epistaxis (nose bleeding) in patients with Hereditary Hemorrhagic Telangiectasia (HHT).
- Trial name
- NCT01402531
- Testing
- Submucosal Bevacizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Diego
Rendu Osler Disease
Calcium-phosphate Complications Induced by IV Iron Supplementation in Patients With Rendu-Osler Disease
Hypophosphatemia induced by treatments with injectable iron is a frequent side effect already reported during marketing. Situations of osteomalacia secondary to these hypophosphatemias are rarer and reported in the form of case…
- Trial name
- OS-LERETRO (NCT05544669)
- Where
- France
- Volunteers
- 220 people
- Sponsor
- University Hospital, Strasbourg, France
Vascular Anomaly, Osler Rendu Disease
Pregnancy in Women With Rare Multisystemic Vascular Diseases: COGRare5 Study
There are no prospective studies of pregnancies for the diseases studied here in (Heredity Hemorrhagic Telangiectasia, Marfan syndrome or related, primary lower limb lymphedema, superficial arteriovenous malformations, and…
- Conditions
- Vascular Anomaly, Osler Rendu Disease, Marfan Syndrome or Related, Lymphedema Primary
- Trial name
- COGRare5 (NCT04194619)
- Testing
- Questionnaire
- Where
- 37 sites in France
- Volunteers
- 400 people
- Sponsor
- Hospices Civils de Lyon
Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
This is a 2-part study evaluating ATV-1601 in participants with moderate to severe HHT. Part 1 is a randomized, double-blind, placebo-controlled study evaluating 3 dosing regimens of ATV-1601.
- Trial name
- NCT07601425
- Testing
- ATV-1601
- Where
- 8 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Atavistik Bio, Inc
Hereditary Haemorrhagic Telangiectasia
Immunological Effects of Iron Supplementation in HHT Disease
Hereditary haemorrhagic telangiectasia (HHT), is a rare genetic vascular disorder with autosomal dominant inheritance. Its prevalence is estimated at approximately 1 in 6,000 individuals in France.
- Trial name
- Fer&RO (NCT07111598)
- Testing
- Blood test at D0, Blood test at D+3 months
- Where
- France
- Volunteers
- 155 people
- Sponsor
- Hospices Civils de Lyon
Hereditary Hemorrhagic Telangiectasia
Counseling Intervention in Hereditary Hemorrhagic Telangiectasia in the COVID Era.
The goal of this interventional study is to determine the incidence of depression, anxiety, sleep disturbances and resilience in a sample of subjects affected by Hereditary Hemorrhagic Telangiectasia.
- Trial name
- NCT05752253
- Testing
- Counseling
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Hepatic Encephalopathy, Minimal Brain Dysfunction
Minimal Hepatic Encephalopathy in Hereditary Hemorrhagic Telangiectasian
HHT or Rendu-Osler-Weber disease is a genetic disease with an autosomal dominant inheritance pattern, characterized by widespread telangiectases that can involve several organs including the intestinal tract and the liver.
- Trial name
- mHE-HHT (NCT03586115)
- Testing
- Critical flicker frequency assessment
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Bari
Hereditary Hemorrhagic Telangiectasia
Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia
This study is one of the three projects of an NIH Rare Disease Clinical Research Consortium. A "consortium" is a group of centres sharing information and resources to perform research.
- Trial name
- BVMC6203 (NCT01158807)
- Where
- 19 sites in United States, Canada and 1 more
- Volunteers
- 2,272 people
- Sponsor
- Unity Health Toronto
Telangiectasia, Hereditary Hemorrhagic, Intracranial Arteriovenous Malformations
Hereditary Hemorrhagic Telangiectasia and Neurovascular Manifestations, in the Danish HHT Database
With a described prevalence of brain arteriovenous malformations (CAVM) of 12.8% in HHT patients, of whom 10% presents with intracranial hemorrhage, HHT pose a risk of devastating intracranial hemorrhage.
- Trial name
- DAN-HEMTEL-VM (NCT05933330)
- Testing
- Brain MRI
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- Odense University Hospital